Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 5:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 2,085 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Alzheimers Disease Clear all
Recruiting Phase 3 Interventional Accepts healthy volunteers

PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620

NCT05456503
View directory record Official record
Conditions
Frontotemporal Lobar Degeneration, Alzheimer Disease, Cognitively Normal
Interventions
[18F]-PI-2620
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 9, 2026, 5:48 AM EDT
Completed Phase 1 Interventional

Telesupport: Evaluation of Professionally Led Support Groups for Caregivers

NCT00259415
View directory record Official record
Conditions
Caregiver Burden
Interventions
Caregiver support via telephone
Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
55 Years and older · Female only
Timeline
Started 2000
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 9, 2026, 5:48 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology

NCT01020838
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Florbetaben (BAY94-9172)
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
21 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
8
States / cities
Sun City, Arizona • Stanford, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 27, 2016 · Synced Oct 9, 2026, 5:48 AM EDT
Recruiting Not applicable Interventional

Central Auditory Processing Modulation Underlying Anxiety Reduction Using Clinically Designed Improvisatory Music

NCT07775625
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Clinically Designed Improvisatory Music, Listening to Storytelling
Other
Lead sponsor
Northwestern University
Other
Eligibility
55 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 9, 2026, 5:48 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Exploring the Utility of [18F]3F4AP for Demyelination Imaging

NCT06999434
View directory record Official record
Conditions
Demyelinating Disorders, MCI, Alzheimer's Disease (AD), MS (Multiple Sclerosis), SCI - Spinal Cord Injury, Spinal Radiculopathy
Interventions
[ 18F]3F4AP, [18F]MK6240, [11C]PIB
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 9, 2026, 5:48 AM EDT
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 9, 2026, 5:48 AM EDT
Completed Phase 3 Interventional

18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

NCT00103649
View directory record Official record
Conditions
Alzheimer Disease
Interventions
xaliproden (SR57746A)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
97
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Oct 9, 2026, 5:48 AM EDT
Completed Not applicable Interventional

An Innovative Caregiver Tool to Assess and Manage Behavioral Symptoms of Dementia

NCT02420535
View directory record Official record
Conditions
Dementia
Interventions
Immediately Receive Tool, One Month Delay
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
21 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Oct 9, 2026, 5:48 AM EDT
Terminated Phase 3 Interventional

Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol

NCT00380276
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MPC-7869
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
55 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
84
States / cities
Alabaster, Alabama • Huntsville, Alabama • Phoenix, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Oct 9, 2026, 5:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose)

NCT02537938
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
NGP 555
Drug
Lead sponsor
NeuroGenetic Pharmaceuticals Inc
Industry
Eligibility
40 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 9, 2026, 5:48 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Depression in Alzheimer's Disease-2

NCT00086138
View directory record Official record
Conditions
Alzheimer's Disease, Depression
Interventions
Sertraline (Zoloft), Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
5
States / cities
Los Angeles, California • Baltimore, Maryland • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 9, 2026, 5:48 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

NCT02649985
View directory record Official record
Conditions
Multiple Sclerosis, Alzheimer's Disease
Interventions
[F-18]PBR06, [C-11]PBR28
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 9, 2026, 5:48 AM EDT
Completed Not applicable Interventional

Network-guided TMS in Early Alzheimer's Disease

NCT04549155
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Duke University
Other
Eligibility
55 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 9, 2026, 5:48 AM EDT
Completed Not applicable Interventional

Using Behavioral Programs to Treat Sleep Problems in Individuals With Alzheimer's Disease

NCT00183378
View directory record Official record
Conditions
Alzheimer Disease, Sleep Initiation and Maintenance Disorders
Interventions
Walking Program, Light Exposure Program, Combined Education, Walking and Light Exposure Program, Routine Medical Care with Education
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
55 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 9, 2026, 5:48 AM EDT
Recruiting Not applicable Interventional

Vestibular Therapy in Alzheimer's Disease

NCT03799991
View directory record Official record
Conditions
Vestibular Diseases, Vestibular Disorder, Alzheimer Disease
Interventions
Vestibular physical therapy, Active control
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 9, 2026, 5:48 AM EDT
Active, not recruiting Not applicable Interventional

Stress and Blood Pressure Management for Caregivers

NCT05734638
View directory record Official record
Conditions
Hypertension, Stress, Psychological
Interventions
MIM-DASH, MIM Only, DASH Only
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
40 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 9, 2026, 5:48 AM EDT
Completed Phase 3 Interventional

Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type

NCT00041678
View directory record Official record
Conditions
Alzheimer Disease
Interventions
aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 95 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
6
States / cities
Rosemead, California • Miami, Florida • Nashville, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 9, 2026, 5:48 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Optimization of Blood Levels of 25(OH)-Vitamin D in African Americans

NCT04939792
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
Vitamin D, Placebo, Vitamin D + L-cysteine, L-cysteine
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years to 65 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 9, 2026, 5:48 AM EDT
Completed No phase listed Observational

Behavioral Expressions in Alzheimer's Disease

NCT02719834
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Acetaminophen, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
65 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 2, 2018 · Synced Oct 9, 2026, 5:48 AM EDT
Completed No phase listed Observational

Effect of Cerefolin®/CerefolinNAC® on Biomarker Measurements

NCT01745198
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease Related Disorders
Interventions
Not listed
Lead sponsor
Pamlab, Inc.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 9, 2026, 5:48 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease

NCT03289143
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Semorinemab, Placebo, [18F]GTP1
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
43
States / cities
Birmingham, Alabama • Glendale, California • Irvine, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 9, 2026, 5:48 AM EDT
Completed Phase 4 Interventional Results available

Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease

NCT00476008
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Memantine, Placebo
Drug
Lead sponsor
Florida Atlantic University
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 9, 2026, 5:48 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer's Disease

NCT00046358
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Lovostatin, Ibuprofen
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 9, 2026, 5:48 AM EDT
Completed Not applicable Interventional

Improving Sleep and Cognition in Alzheimer's Disease

NCT05200208
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Citicoline supplement, Placebo
Dietary Supplement · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 9, 2026, 5:48 AM EDT